Personalizing breast cancer staging by the inclusion of ER, PR, and HER2

JAMA Surgery

Volumn 149, Issue 2, 2014, Pages 125-129

  Bagaria, Sanjay P ^a   Ray, Partha S ^b,c   Sim, Myung Shin ^d   Ye, Xing ^d   Shamonki, Jaime M ^d   Cui, Xiaojiang ^e   Giuliano, Armando E ^e  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c Carle Cancer Center   (United States)

^d JOHN WAYNE CANCER INSTITUTE   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; ESTROGEN RECEPTOR ALPHA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84894583221     PISSN: 21686254     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamasurg.2013.3181     Document Type: Article

References (27)

1. Edge SBBD, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
2. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502.
3. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-2795.
4. Allred DC, Carlson RW, Berry DA, et al. NCCN task force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw. 2009;7(suppl 6):S1-S23.
5. Iwamoto T, Booser D, Valero V, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1%to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012;30(7):729-734.
6. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291(16):1972-1977.
7. Bland JM, Altman DG. Survival probabilities (the Kaplan-Meier method). BMJ. 1998;317(7172):1572. doi:10.1136/bmj.317.7172.1572.
8. Bland JM, Altman DG. The logrank test. BMJ. 2004;328(7447):1073. doi:10.1136/bmj.328.7447.1073.
9. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15, pt 1):4429-4434.
10. Ihemelandu CU, Leffall LD Jr, Dewitty RL, et al. Molecular breast cancer subtypes in premenopausal African-Americanwomen, tumor biologic factors and clinical outcome. Ann Surg Oncol. 2007;14(10):2994- 3003.
11. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26(26):4282-4288.
12. Barbieri V, Sanpaolo P, Genovesi D. Prognostic impact of triple negative phenotype in conservatively treated breast cancer. Breast J. 2011;17(4):377-382.
13. Elnashar AT, Ali SM, Gaber A. The prognostic value of triple negative in stage II/III breast cancer. J Oncol Pharm Pract. 2012;18(1):68-75.
14. Buyse M, Loi S, van't Veer L, et al; TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98(17):1183-1192.
15. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009.
16. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.
17. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365(9460):671-679.
18. Tan GH, ChooWY, Taib NA, Yip CH. Factors associated with HER2 overexpression in breast cancer: experience in an Asian developing country. Asian Pac J Cancer Prev. 2009;10(5):837-840.
19. Chaiwun B, Nakrungsee S, Sukhamwang N, Srisukho S. A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study. Breast Cancer. 2010;17(1):35-41.
20. Yip CH, Pathy NB, Uiterwaal CS, et al. Factors affecting estrogen receptor status in a multiracial Asian country: an analysis of 3557 cases. Breast. 2011;20(suppl 2):S60-S64.
21. Dey S, Boffetta P, Mathews A, Brennan P, Soliman A, Mathew A. Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum, South India. Int J Cancer. 2009;125(7):1663-1670.
22. Masood S, Vass L, Ibarra JA Jr, et al; Breast Health Global Initiative Pathology Focus Group. Breast pathology guideline implementation in lowand middle-income countries. Cancer. 2008;113(8)(suppl):2297-2304.
23. Jeruss JS,Mittendorf EA, Tucker SL, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008;26(2):246-252.
24. YiM,Mittendorf EA, Cormier JN, et al. Novel staging system for predicting disease-specific survival in patientswith breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol. 2011;29(35):4654-4661.
25. Park YH, Lee SJ, Cho EY, et al. Clinical relevance of TNM staging system according to breast cancer subtypes. Ann Oncol. 2011;22(7):1554-1560.
26. Veronesi U, Zurrida S, Viale G, Galimberti V, Arnone P, Nolè F. Rethinking TNM: a breast cancer classification to guide to treatment and facilitate research. Breast J. 2009;15(3):291-295.
27. Burke HB. Outcome prediction and the future of the TNM staging system. J Natl Cancer Inst. 2004;96(19):1408-1409.